LiGHT 2026

Boston Scientifics PFA system achieves efficacy and safety endpoints

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

WebMD Ignite Ruby Transforms Healthcare Marketing...

WebMD Ignite has announced the launch of WebMD Ignite...

Mayo Clinic Study Validates AI Tool...

Researchers at Mayo Clinic have found that an artificial...

MHRA Outlines New Agenda for AI...

The United Kingdomโ€™s Medicines and Healthcare products Regulatory Agency...

Boston Scientific has announced the achievement of primary efficacy and safety endpoints in the ADVENT Study of the FARAPULSE Pulsed Field Ablation (PFA) System.

FARAPULSE is a nonthermal treatment, which selectively applies electric fields for ablating heart tissue in patients with atrial fibrillation (AF).

The pivotal, randomised clinical study compared the efficacy and safety of the system versus standard-of-care ablation, either cryoablation or radiofrequency, to treat patients with paroxysmal, or intermittent, AF.

Over the course of 12 months, the data indicated that the system was as effective as standard-of-care treatments, even though most physicians had only worked with thermal ablation in the past.

The prospective, multicentre trial included 607 US patients with paroxysmal AF who had earlier been unsuccessfully treated with a minimum of one anti-arrhythmic drug.

Boston Scientific global chief medical officer and senior vice-president Kenneth Stein said: โ€œThese data underscore the superior procedural efficiency of this novel technology, and real-world use continues to yield strong safety and efficacy outcomes.

โ€œThe performance of the FARAPULSE PFA System in this trial is an encouraging sign of the potential utilisation of the device in the US and we look forward to further studying the system for the treatment of patients with persistent AF in the ADVANTAGE AF clinical trial, which began enrolment earlier this year.โ€

 

In 2021, the company received CE Mark for the FARAPULSE PFA System. So far, it has been used to treat over 25,000 patients across the globe.

 

Never miss a healthcare headline

Healthcare moves fast โ€“ stay on top of it with our must - read briefings.

  • The top hospital and healthcare stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments transforming global healthcare management

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media PackNow

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Latest stories

Related stories

Mayo Clinic Study Validates AI Tool DEXI for Skin Lesion Assessment

Researchers at Mayo Clinic have found that an artificial...

MHRA Outlines New Agenda for AI Medical Devices at AdvaMed

The United Kingdomโ€™s Medicines and Healthcare products Regulatory Agency...

UK Confirms Indefinite Use of CE Marked Medical Devices

The United Kingdom government has officially confirmed the indefinite...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป